I am sure everyone heard that major hedge funds unloaded shares Deutsche Bank AG (NYSE:DB) today. When the news broke, the stock took a major dive, taking the market with it. Everyone is expecting a default and possible bailout from Germany or the European Union. Shareholders would be wiped out and its possible many other banks would be hurt in the aftermath. Essentially, it is a Bear Sterns or even Lehman Brothers situation.

So why did some institutional traders buy Deutsche Bank today? Simply put, they are betting today was a freakout and it could bounce tomorrow. Why do they think that? A simple trend line connecting the lows. If you note the stock chart below, and connect lows, the stock price hit that line today. Notice how every time the stock hit this line it bounced. Sometimes charts are just that simple to read. Time will tell if this risky trade pans out, it is not for the avearge investor. Far too much risk.

Whenever I see the $TEVA ticker, I’m thinking about those comfortable Teva sandals, but $TEVA is actually Teva Pharmaceutical Industries (NYSE: TEVA). You have to look at $DECK for the other Teva.  $TEVA hit its all-time high $72.31 in July 2015 and has been moving steadily downward since. Yesterday, it fell almost 5% closing at $46.29. It is now very near some serious support with a 75% fib retrace and gap window about a buck lower, and another buck lower from there is a gap fill. You can also see in the weekly chart below the down-sloping trend line coming into play in this area. Anywhere around the $44-$45 area is a screaming buy to me for a quick $2-$3 bounce.

Announces Pricing of Public Offering of Common Stock

NEW YORK - September 29, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $1.25. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about October 4, 2016, subject to customary closing conditions.

The gross proceeds to Actinium from this offering is expected to be $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Actinium. Actinium currently intends to use the net proceeds from the sale of securities for general corporate purposes, including capital expenditures, the advancement of its drug candidates in clinical trials, such as Iomab™-B and Actimab™- A, preclinical trials, and to meet working capital needs.

Launches the Inaugural Reign Sapphire Jewelry Collections Look Book and Style Guide

BEVERLY HILLS, CA - September 29, 2016 (Investorideas.com Newswire) Reign Sapphire Corporation, (OTCQB: RGNP) ("Reign" or the "Company"), which produces and markets Australian Sapphire Jewelry, today announced the launch of its Inaugural Reign Sapphires Jewelry Collections Look Book and Style Guide, presenting Reign's lifestyle campaign and jewelry collections recently launched on www.reignsapphires.com.

The Reign Sapphires Jewelry Collections Look Book and Style Guide features images of Reign Sapphires's three distinct inaugural jewelry collections, Reign Opulence, Reign Signature and Reign Classics, featuring rings, bracelets and necklaces, predominantly comprised of 1.5mm to 4.5mm diamond and princess cut sapphire melees.

"We are thrilled to present our Look Book and Style Guide to the world of fashion and jewelry," said Joseph Segelman, CEO.